Navigation Links
Amicus Therapeutics Announces First Quarter 2008 Financial Results
Date:5/13/2008

SFAS No. 123R. Amicus believes that excluding the

impact of expensing stock options better reflects the recurring

economic characteristics of its business.

(2) Other items -- Non-GAAP net loss and diluted net loss per common share

exclude other unusual or non-recurring items that are evaluated on an

individual basis. Amicus' evaluation of whether to exclude an item for

purposes of determining its non-GAAP financial measures considers both

the quantitative and qualitative aspects of the item, including, among

other things (i) its size and nature, (ii) whether or not it relates

to its ongoing business operations, and (iii) whether or not Amicus

expects it to occur as part of its normal business on a regular basis.

Items excluded for purposes of determining non-GAAP net loss and

diluted net loss per common share include deemed dividends, preferred

stock accretion, and changes in the fair value of warrant liability.

Conference Call and Webcast: First Quarter Financial Results

Amicus Therapeutics will host a conference call and webcast today, Tuesday, May 13, 2008, at 5:00 P.M. EDT to review financial results and recent developments. Interested participants and investors may access the teleconference call by dialing 877-397-0284 (U.S./Canada) or 719-325-4871 (international).

The webcast of the call can be accessed on the Investor section of Amicus' Web site at http://www.amicustherapeutics.com under Investors: Events and Presentations. Web participants are encouraged to go to the Web site 15 minutes prior to the start of the call to register, download and install any necessary software. After the live webcast, a replay will remain available in the Investors section of Amicus' Web site for 90 days.

A telephonic replay will also be available for seven days be
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech 2007 Conference
2. Amicus Therapeutics Announces Third Quarter 2007 Financial Results
3. Meredith Martin Addy Named Chair of AIPLAs Amicus Committee
4. Amicus Therapeutics to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference
5. Amicus Therapeutics to Host R&D Day
6. Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal(TM) for Fabry Disease
7. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
8. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
9. Amicus Therapeutics to Present at the BIO CEO & Investor Conference 2008
10. Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease
11. Amicus Therapeutics to Present at the Morgan Stanley Global Healthcare Unplugged Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/28/2014)... (PRWEB) November 28, 2014 The report ... for all the important sub-segments of the market, in ... It maps the growth rates and market sizes for ... poised to witness rapid growth. It also includes analysis ... These company profiles include the financial performances, product portfolios, ...
(Date:11/27/2014)... 2014 First articles published ... Elsevier , a world-leading provider of scientific, ... to announce the launch of a new journal: ... The launch of Extreme Mechanics Letters ... forefront of applied sciences such as micro and nanotechnologies, ...
(Date:11/26/2014)... The report on the Global Smart Sensor Market in ... revenue forecasts and market trends. It expects the market ... to 2018. At the projected rate, the market is ... 2018. , Browse through the Global Smart Sensor Market ... market segmentation and in-depth analysis supported by a list ...
(Date:11/26/2014)... 2014 The announced sales of three healthcare ... looking to expand in non-healthcare areas, says Kalorama Information. ... research firm says that  Siemens is the third largest ... of the IVD market , with 5.5 billion in ... composition would likely affect IVD market shares.  ...
Breaking Biology Technology:Glycomics Market by Application, Product & End-Users is estimated to reach $928.11 Million by 2019 - New Research Report by MarketsandMarkets 2Glycomics Market by Application, Product & End-Users is estimated to reach $928.11 Million by 2019 - New Research Report by MarketsandMarkets 3Glycomics Market by Application, Product & End-Users is estimated to reach $928.11 Million by 2019 - New Research Report by MarketsandMarkets 4Glycomics Market by Application, Product & End-Users is estimated to reach $928.11 Million by 2019 - New Research Report by MarketsandMarkets 5Elsevier Announces the Launch of a New Journal: Extreme Mechanics Letters 2Elsevier Announces the Launch of a New Journal: Extreme Mechanics Letters 3Global Smart Sensor Market in Building Automation is expected to reach a value of $1,415.6 million by 2018 - Report by MicroMarket Monitor 2Global Smart Sensor Market in Building Automation is expected to reach a value of $1,415.6 million by 2018 - Report by MicroMarket Monitor 3Global Smart Sensor Market in Building Automation is expected to reach a value of $1,415.6 million by 2018 - Report by MicroMarket Monitor 4Kalorama: Sale of Three Siemens Healthcare Units Raises Questions About Firm's IVD Future 2
... Inc. today announced that data from its phase 1/2 ... be highlighted in an oral presentation at the 50th ... in San Francisco, California, on December 9, 2008. , ... of the XIAP Antisense Oligonucleotide (AEG35156) in Combination with ...
... BioMarin Pharmaceutical,Inc. (Nasdaq: BMRN ) today announced that ... update at the Piper,Jaffray Healthcare Conference in New York City ... Interested parties may access a ... of the BioMarin website, http://www.BMRN.com . A,replay of the ...
... JOLLA, Calif., Nov. 25 TorreyPines Therapeutics, Inc.,(Nasdaq: ... from Eli Lilly & Company,a reduction in certain royalty ... sales of TorreyPines, clinical-stage compounds NGX426 and tezampanel,should either ... rate will be reduced three percentage points and the ...
Cached Biology Technology:Aegera Therapeutics' phase 1/2 clinical trial results selected for oral presentation at 2008 ASH Annual Meeting 2Aegera Therapeutics' phase 1/2 clinical trial results selected for oral presentation at 2008 ASH Annual Meeting 3BioMarin to Present at the Piper Jaffray Healthcare Conference 2TorreyPines Therapeutics Enters into Agreement to Reduce Royalty Rates and Delay Clinical Milestone Payments Due to Eli Lilly for NGX426 and Tezampanel 2
(Date:11/21/2014)... 20, 2014 C-Labs LLC, a leading provider ... Things (IoT), today announced the appointment of John ... Previously a strategic advisor to the firm, Mr. Traynor ... Traynor is based out of the C-Labs office in ... Chris Muench , Chief Executive Officer. ...
(Date:11/18/2014)... 18, 2014   EyeLock Inc. , a ... MorphoTrust USA (Safran), a leading U.S. ... a strategic partnership to offer comprehensive biometric identity ... (MVA), airport screening and financial services markets. ... serves consumers through a nationwide network of 1,100 ...
(Date:11/7/2014)... Researchers led by Dr. Debra Auguste, associate professor, ... at The City College of New York, have ... treatment for one of the most aggressive forms ... (TNBCs) have a high mortality rate owing to ... effective therapeutic options. However, Professor Auguste,s team, discovered ...
Breaking Biology News(10 mins):C-Labs Names Former Microsoft and Bsquare Executive as Chief Operating Officer 2EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 2EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 3
... Researchers have long known that humans lack a key enzyme ... even plants -- that reverses severe sun damage. For ... at the atomic level to repair sun-damaged DNA. The ... prevention. In the early online edition of the journal ...
... Eeva Karjalainen, of the Finnish Forest Research Institute, Metla, "feel ... not many of us know that there is also scientific ... and other natural, green settings can reduce stress, ... Forest visits may also strengthen our immune system by increasing ...
... (SACRAMENTO, Calif.) A shared decision-making process would assist ... challenging and controversial choices presented when infants are born ... are being considered for elective corrective surgery, a new ... instances in which infants are born with conditions that ...
Cached Biology News:Researchers discover how key enzyme repairs sun-damaged DNA 2Study recommends that parents, physicians share decisions in sex development disorder surgery 2Study recommends that parents, physicians share decisions in sex development disorder surgery 3Study recommends that parents, physicians share decisions in sex development disorder surgery 4
Edited by D. Rickwood, T.C. Ford and J.T. Steensgaard (1994) Compiles core data required by researchers carrying out any centrifugal separation, whether working with cells, organelles or macromolec...
Rat neural stem cell kits are intended for the in vitro growth and commitment to neuronal and glial lineage differentiation, of cultured fetal rat neural stem and progenitor cells expanded using FGF-...
Antibodies were affinity purified using epitopes specific to JLP immobilized on solid support....
... Price (1996) • This issue ... chemistry and the purification and ... on the following procedures is ... amino acid analysis and the ...
Biology Products: